JP7330896B2 - 抗ｔｓｌｐ抗体による喘息治療 - Google Patents

抗ｔｓｌｐ抗体による喘息治療 Download PDF

Info

Publication number
JP7330896B2
JP7330896B2 JP2019555854A JP2019555854A JP7330896B2 JP 7330896 B2 JP7330896 B2 JP 7330896B2 JP 2019555854 A JP2019555854 A JP 2019555854A JP 2019555854 A JP2019555854 A JP 2019555854A JP 7330896 B2 JP7330896 B2 JP 7330896B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
tslp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019555854A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516647A5 (OSRAM
JP2020516647A (ja
JPWO2018191479A5 (OSRAM
Inventor
ジェーン アール． パーネス，
ジャネット グリフィス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2020516647A publication Critical patent/JP2020516647A/ja
Publication of JP2020516647A5 publication Critical patent/JP2020516647A5/ja
Publication of JPWO2018191479A5 publication Critical patent/JPWO2018191479A5/ja
Priority to JP2023080295A priority Critical patent/JP2023099233A/ja
Application granted granted Critical
Publication of JP7330896B2 publication Critical patent/JP7330896B2/ja
Priority to JP2024127900A priority patent/JP2024150751A/ja
Priority to JP2025147176A priority patent/JP2025170430A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019555854A 2017-04-12 2018-04-12 抗ｔｓｌｐ抗体による喘息治療 Active JP7330896B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023080295A JP2023099233A (ja) 2017-04-12 2023-05-15 抗ｔｓｌｐ抗体による喘息治療
JP2024127900A JP2024150751A (ja) 2017-04-12 2024-08-02 抗ｔｓｌｐ抗体による喘息治療
JP2025147176A JP2025170430A (ja) 2017-04-12 2025-09-04 抗ｔｓｌｐ抗体による喘息治療

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US62/484,864 2017-04-12
US201762553575P 2017-09-01 2017-09-01
US201762553477P 2017-09-01 2017-09-01
US62/553,477 2017-09-01
US62/553,575 2017-09-01
PCT/US2018/027271 WO2018191479A1 (en) 2017-04-12 2018-04-12 Treatment of asthma with anti-tslp antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023080295A Division JP2023099233A (ja) 2017-04-12 2023-05-15 抗ｔｓｌｐ抗体による喘息治療

Publications (4)

Publication Number Publication Date
JP2020516647A JP2020516647A (ja) 2020-06-11
JP2020516647A5 JP2020516647A5 (OSRAM) 2021-05-20
JPWO2018191479A5 JPWO2018191479A5 (OSRAM) 2022-11-22
JP7330896B2 true JP7330896B2 (ja) 2023-08-22

Family

ID=62092313

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019555854A Active JP7330896B2 (ja) 2017-04-12 2018-04-12 抗ｔｓｌｐ抗体による喘息治療
JP2023080295A Withdrawn JP2023099233A (ja) 2017-04-12 2023-05-15 抗ｔｓｌｐ抗体による喘息治療
JP2024127900A Pending JP2024150751A (ja) 2017-04-12 2024-08-02 抗ｔｓｌｐ抗体による喘息治療
JP2025147176A Pending JP2025170430A (ja) 2017-04-12 2025-09-04 抗ｔｓｌｐ抗体による喘息治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023080295A Withdrawn JP2023099233A (ja) 2017-04-12 2023-05-15 抗ｔｓｌｐ抗体による喘息治療
JP2024127900A Pending JP2024150751A (ja) 2017-04-12 2024-08-02 抗ｔｓｌｐ抗体による喘息治療
JP2025147176A Pending JP2025170430A (ja) 2017-04-12 2025-09-04 抗ｔｓｌｐ抗体による喘息治療

Country Status (21)

Country Link
US (3) US10828365B2 (OSRAM)
EP (1) EP3609917A1 (OSRAM)
JP (4) JP7330896B2 (OSRAM)
KR (2) KR20240070727A (OSRAM)
CN (1) CN110573525A (OSRAM)
AU (2) AU2018253118B2 (OSRAM)
BR (1) BR112019021482A2 (OSRAM)
CA (1) CA3059364A1 (OSRAM)
CL (1) CL2019002897A1 (OSRAM)
CO (1) CO2019011462A2 (OSRAM)
IL (1) IL269791B (OSRAM)
JO (1) JOP20190243A1 (OSRAM)
MX (1) MX2019012158A (OSRAM)
MY (1) MY207509A (OSRAM)
PE (1) PE20200484A1 (OSRAM)
PH (1) PH12019502331A1 (OSRAM)
SG (1) SG11201909322VA (OSRAM)
TN (1) TN2019000289A1 (OSRAM)
TW (2) TWI856945B (OSRAM)
UY (1) UY37676A (OSRAM)
WO (1) WO2018191479A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023099233A (ja) * 2017-04-12 2023-07-11 アムジェン インコーポレイテッド 抗ｔｓｌｐ抗体による喘息治療

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3347377B1 (en) * 2015-09-09 2021-02-17 Novartis AG Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
TW202110882A (zh) 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
AU2020311432A1 (en) * 2019-07-11 2022-02-03 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合ｔｓｌｐ及びその使用
RS66646B1 (sr) * 2019-10-28 2025-04-30 Medimmune Ltd Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe
CN112876564B (zh) * 2019-11-29 2022-07-15 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
US20220363781A1 (en) * 2019-12-13 2022-11-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN115279404A (zh) * 2020-02-13 2022-11-01 安进公司 人抗tslp抗体的配制品及治疗炎性疾病的方法
WO2021163588A1 (en) * 2020-02-13 2021-08-19 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
MX2022010120A (es) * 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
CN113388035A (zh) * 2020-03-13 2021-09-14 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
TW202229339A (zh) * 2020-12-03 2022-08-01 大陸商江蘇恒瑞醫藥股份有限公司 結合胸腺基質淋巴細胞生成素的抗體及其應用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
MX2023009971A (es) * 2021-03-03 2023-09-05 Chia Tai Tianqing Pharmaceutical Group Co Ltd Composicion farmaceutica que contiene anticuerpo anti-tslp.
KR20230172508A (ko) * 2021-04-19 2023-12-22 메디뮨 리미티드 안정성이 개선된 항-tslp fab
BR112023022041A2 (pt) 2021-04-23 2023-12-26 Amgen Inc Anticorpos anti-tslp modificados
EP4326766A1 (en) 2021-04-23 2024-02-28 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117106084B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176A (zh) * 2022-06-24 2024-01-02 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
TW202523697A (zh) * 2023-08-25 2025-06-16 美商普羅特歐拉吉克適美國公司 抗ｔｓｌｐ抗體構築體及其用途
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
BR112016008694A2 (pt) * 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
MX2017001531A (es) * 2014-08-08 2017-05-15 Alector Llc Anticuerpos anti-trem2 y metodos de uso de los mismos.
WO2016142426A1 (en) 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J. Allergy Clin. Immunol., 2018.2, Vol.141, No.2, Suppl., AB80, #257
N. Engl. J. Med., 2014, Vol.370, No.22, pp.2102-2110
N. Engl. J. Med., 2017.9, Vol.377, No.10, pp.936-946
Study NCT02054130 on Date: January 6, 2017 (v9)，ClinicalTrials.gov archive[online]，2017年1月6日，[2022年4月27日検索]，<URL: https://clinicaltrials.gov/ct2/history/NCT02054130>
Study NCT02512900 on Date: January 3, 2017 (v5)，ClinicalTrials.govarchive[online]，2017年1月3日，[2022年4月27日検索]，<URL: https://clinicaltrials.gov/ct2/history/NCT02512900>

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023099233A (ja) * 2017-04-12 2023-07-11 アムジェン インコーポレイテッド 抗ｔｓｌｐ抗体による喘息治療

Also Published As

Publication number Publication date
KR20190140956A (ko) 2019-12-20
TW201838652A (zh) 2018-11-01
JP2024150751A (ja) 2024-10-23
AU2018253118A1 (en) 2019-10-24
IL269791B (en) 2022-07-01
SG11201909322VA (en) 2019-11-28
CL2019002897A1 (es) 2020-03-06
TWI856945B (zh) 2024-10-01
CN110573525A (zh) 2019-12-13
KR102666879B1 (ko) 2024-05-23
KR20240070727A (ko) 2024-05-21
US10828365B2 (en) 2020-11-10
US20250032608A1 (en) 2025-01-30
US20210052726A1 (en) 2021-02-25
MX2019012158A (es) 2019-12-16
EP3609917A1 (en) 2020-02-19
CA3059364A1 (en) 2018-10-18
TW202523688A (zh) 2025-06-16
BR112019021482A2 (pt) 2020-05-12
AU2025204735A1 (en) 2025-07-17
PH12019502331A1 (en) 2020-09-28
CO2019011462A2 (es) 2019-10-31
AU2018253118B2 (en) 2025-04-10
TN2019000289A1 (en) 2021-05-07
JOP20190243A1 (ar) 2019-10-13
JP2023099233A (ja) 2023-07-11
IL269791A (en) 2019-11-28
PE20200484A1 (es) 2020-03-03
UY37676A (es) 2018-10-31
JP2025170430A (ja) 2025-11-18
US20180296669A1 (en) 2018-10-18
WO2018191479A1 (en) 2018-10-18
MY207509A (en) 2025-02-28
JP2020516647A (ja) 2020-06-11

Similar Documents

Publication Publication Date Title
JP7330896B2 (ja) 抗ｔｓｌｐ抗体による喘息治療
EP2152290B1 (en) Methods for administering anti-il-5 antibodies
Menzella et al. Tailored therapy for severe asthma
EP2627673B1 (en) Therapies for improving pulmonary function
US20180319889A1 (en) Method and medicament for treating airway and/or lung diseases
TW202304980A (zh) 經修飾的抗ｔｓｌｐ抗體
TW202144004A (zh) 人抗tslp 抗體之配製物及其使用方法
US20230073888A1 (en) Treatment of atopic dermatitis with anti-tslp antibody
TW202509066A (zh) 用抗ｔｓｌｐ抗體治療皮質類固醇依賴性氣喘
AU2024274293A9 (en) Treatment of corticosteroid dependent asthma with anti-tslp antibody
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
KR20250140101A (ko) 항-tslp 항체를 이용한 만성 비부비동염의 치료
WO2025221247A1 (en) Treatment of eosinophilic esophagitis with anti-tslp antibody
Hammad et al. Immunotherapy for asthma
HK1188603B (en) Therapies for improving pulmonary function
HK1188603A (en) Therapies for improving pulmonary function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221007

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230626

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230809

R150 Certificate of patent or registration of utility model

Ref document number: 7330896

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150